Trial Profile
A Phase I/II Study to Assess the Safety and Therapeutic Effect of INCB007839 in Combination With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Aderbasib (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 06 Oct 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 13 Dec 2010 New trial record